Parameter
| Biomarker | CD19 | Full name | Cluster of differentiation 19 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Therapeutic targets (alternative targets for relapsed/refractory diseases) |
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Biopsy specimens during recurrence (immunohistochemistry, flow cytometry) | ||
| Pathobiological Mechanisms | During relapse, CD19 expression remained stable without loss of expression, which may be related to the conservation of this marker in B-cell development and tumor phenotypes. | ||||
| Clinical Availability Status | Clinical potential/research validation: The conservation of CD19 expression during relapse supports its use as an alternative target after anti-CD19 therapy failure. | ||||
| Notes and Dynamics | All patients with CD19 positivity at relapse (14/14) maintained positive results, providing a novel basis for anti-CD19 targeted therapy in relapsed/refractory B-cell NHL. | ||||